

COMUNICACIÓN DE OTRA INFORMACIÓN RELEVANTE

27 de abril de 2021

En virtud de lo previsto en el artículo 17 del Reglamento (UE) nº 596/2014 sobre abuso de mercado y en el artículo 228 del texto refundido de la Ley del Mercado de Valores, aprobado por el Real Decreto Legislativo 4/2015, de 23 de octubre, y disposiciones concordantes, así como en la Circular 3/2020 de BME MTF Equity, ponemos en su conocimiento:

Se adjunta presentación de resultados de Atrys Health S.A. correspondiente al ejercicio 2020.

Para presentar los resultados del ejercicio 2020 se **celebrará un “webinar” este martes 27 de abril de 2021 a las 12:00** y contará con la presencia por parte de la compañía de Santiago de Torres (Presidente Ejecutivo), Isabel Lozano (CEO) y José Maria Huch (CFO).

El “webinar” se realizará en colaboración con Rankia.com y contará con un turno de preguntas y respuestas.

Para acceder es preciso ser usuario registrado de Rankia o inscribirse gratuitamente. Se podrá acceder al “webinar” en el siguiente enlace:


<https://www.rankia.com/acciones/atrys-health-atry/webinars/3939-presentacion-resultados-atrys-health-2020>

En cumplimiento de lo dispuesto en la Circular 3/2020 del BME Growth se deja expresa constancia que la información comunicada ha sido elaborada bajo exclusiva responsabilidad del emisor y sus administradores.

Madrid, 27 de abril de 2021.

Doña Isabel Lozano Fernández.

Consejera Delegada.



2020 year-end report

April, 2020.

Santiago de Torres
Executive Chairman

Isabel Lozano
CEO

José M^a Huch
CFO

Disclaimer and Cautionary Statements

El presente documento y la conferencia de resultados (incluyendo el turno de preguntas y respuestas) puede contener manifestaciones de futuro e información (de ahora en adelante, “Manifestaciones”) relacionados con ATRYS HEALTH, S.A, o el Grupo ATRYS (de ahora en adelante indistintamente “ATRYS”, la “Compañía” o el “Grupo”). Estas manifestaciones pueden incluir proyecciones y estimaciones financieras con asunciones, declaraciones relativas a planes, objetivos, y expectativas que pueden referirse a diversas materias, entre otras, a la base de clientes y a su evolución, al crecimiento de las distintas líneas de negocio, a la cuota de mercado, a los resultados de la compañía y a otros aspectos relativos a la actividad y situación de la misma.

Las manifestaciones de futuro o previsiones contenidas en este documento pueden ser identificadas, en determinados casos, por la utilización de palabras como “expectativas”, “anticipación”, “propósito”, “creencia” o de un lenguaje similar, o su correspondiente forma negativa, o por la propia naturaleza de la predicción que tienen las cuestiones referidas a estrategias o planes o intenciones. Estas manifestaciones de futuro o previsiones reflejan las opiniones de ATRYS respecto a sucesos futuros, no constituyen, por su propia naturaleza, garantías de un futuro cumplimiento, encontrándose condicionadas por riesgos e incertidumbres que podrían determinar que los desarrollos y resultados finales difieran materialmente de los puestos de manifiesto en estas intenciones, expectativas o previsiones. Entre tales riesgos e incertidumbres están aquellos identificados en los documentos con información más completa registrado por ATRYS ante los diferentes organismos supervisores de los mercados de valores en los que cotiza su acción, y en particular, ante la Comisión Nacional del Mercado de Valores.

Salvo en la medida en que lo requiera la ley aplicable, ATRYS no asume ninguna obligación de actualizar públicamente el resultado de cualquier revisión que pudiera realizar de estas manifestaciones para adaptarla a hechos o circunstancias posteriores a este documento, incluidos, entre otros, cambios en el negocio de la Compañía, en su estrategia de desarrollo de negocio o cualquier posible circunstancia sobrevenida. Este documento puede contener información financiera resumida, non-GAAP o información no auditada. La información contenida en el mismo debe leerse en conjunto y está sujeta a toda la información pública disponible sobre la Compañía, incluyendo, en su caso, otros documentos emitidos por la Compañía que contengan información más completa.

Por último, se hace constar que ni este documento ni nada de lo aquí contenido constituye una oferta de compra, venta o canje, o una solicitud de una oferta de compra, venta o canje de valores, o una recomendación o asesoramiento sobre ningún valor.

This document and the conference-call webcast (including the Q&A session) may contain forward looking statements and information (hereinafter, the “Statements”) relating to ATRYS HEALTH .S.A., or ATRYS Group, (hereinafter indistinctly, “ATRYS”, the “Company” or the “Group”) or otherwise. These Statements may include financial forecasts and estimates based on assumptions or statements regarding plans, objectives and expectations that make reference to different matters, such as the customer base and its evolutions, growth of the different business lines and of the global business, market share, possible acquisitions, divestitures or other transactions, Company’s results and other aspects related to the activity and situations of the Company.

The Statements can be identified, in certain cases, through the use of words such as “forecast”, “expectations”, “anticipation”, “aspiration”, “purpose”, “estimates”, “Plan” or similar expressions or variations of such expressions. These Statements reflect the current views of ATRYS with respect of future events, do not represent, by their own nature, any guarantee of the future fulfilment, and are subject to risks and uncertainties that could cause the final developments and results to materially differ from those expressed or implied by such Statements. These risks and uncertainties include those identified in the documents containing more comprehensive information filed by ATRYS before the different supervisory authorities of the securities markets in which its shares are listed and, in particular, the Mercado Alternativo Bursátil (MaB).

Except as required by applicable law, ATRYS does not assume any obligation to publicly update the Statements to adapt them to events or circumstances taking place after the date hereof, including changes in the Company’s business or business development strategy or any other unexpected circumstance.



This document and the conference-call (including the Q&A session) may contain summarized, non-audited or non-GAAP financial information. The information contained herein and therein should therefore be considered as a whole and in conjunction with all the public information regarding the Company available, including any other documents released by the Company that may contain more detailed information.

Neither this document nor the conference-call (including the Q&A session) nor any of their contents constitute an offer to purchase, sale or exchange any security, a solicitation of any offer to purchase, sale or exchange of any security, or recommendation or advice regarding any security.

INTRODUCTION




ATRYS: Our trip



- The integration of **ASPY** (takeover bid acceptance >95% as of April 26) will **transform Atrys into a global healthcare player**

Work in progress to become a 360° health company offering services to cover the entire spectrum of the healthcare cycle, from prevention to long-term treatments.



Health prevention is proved to be the future of healthcare systems, helping:

PATIENTS through earlier detection of risk factors / illnesses and their early treatment

Introduction of B2C business in Spain with ASPY network of over 230 clinical sites covering >1 million people that will enhance Atrys customer base.



itms - July 2020

◇ atrys division

Leading company in telecardiology and teleradiology in Chile, with presence in Colombia, Brazil and Peru. The acquisition allows ATRYS to lead the telemedicine industry by market share in Chile, Spain and Colombia.

2020 main figures: €15.2M turnover and €4.1M Adjusted EBITDA¹.



AxisMed - August 2020

◇ atrys division

Former Telefonica Group company and a reference in Brazil for population health management. Axismed combines the experience of its medical team, which includes a wide range of general practitioners and specialists (psychologists, nutritionist, etc.), with business intelligence to obtain health profiles and segmentation that allow it to provide personalized health care guidance.

2020 main figures: €3.2M turnover and -€0.25M Adjusted EBITDA.



Genetix - October 2020

◇ atrys division

Spanish company that has become one of the reference centers in the genomic sector in Spain, mainly focused in genetics applied to oncology, an activity that perfectly fits the Atrys pathology business.

2020 main figures: €6.9M turnover and €3.6M Adjusted EBITDA.

¹Adjusted EBITDA = Does not include one-off expenses.



Lenitudes - February 2021
centro médico avançado

Lenitudes is a Portuguese group that operates in the health and medical services sector offering a complete range of radio-diagnostic services, nuclear medicine, radiotherapy, chemotherapy and other clinical oncology services. The whole price has been paid to its former owner, MCH (PE fund), in Atrys shares at a value of €7.25 per share.

2020 main figures: €11.7M turnover and €2.1M Adjusted EBITDA.

radio-onkologie - March 2021

Swiss company founded in 2003 that offers radiotherapy treatments for cancer pathologies. It has two centers, one in Liestal and the other in Allschwil (both in the Basel-Switzerland area).

2020 main figures: €5.8M turnover and €3.0M EBITDA.



ASPY - May 2021 (expected)

Spanish Group with a network of 234 centers and two main business lines: *ASPY Prevención* providing services related to occupational health, and *ASPY Salud* providing healthcare services beyond the scope of prevention.

2020e main figures: €98.5M turnover¹ and €17.5M EBITDA¹.

¹Proforma figures = Includes full year impact of 2020 acquisitions (Conversia)

Over the last 5 years the Group has scaled up from nearly scratch to:

- Become the world leader in teleradiology and telecardiology in Spanish language.
- Setting the foundations to become a leading european group in oncology diagnosis and treatments with a strong footprint in Spain, Portugal and Switzerland.

	2016	2021e ¹
Turnover	€4.5M	€175.0M
Adjusted EBITDA ²	€1.0M	€41.0M
No. of countries	1	7
No. of medical staff	100	1,000
No. Radiotherapy LINACs ³	1	9
No. medical diagnosis per year	177,000	>5M
No. employees	44	>2,000
R&D Investment	€1.4M	€3.0M


¹ Aggregated Proforma **Budget** = Includes full year impact of 2021 acquisitions (ASPY, Lenitudes and ROAG).

² Adjusted EBITDA = Does not include one-off expenses.


³ Linear Accelerators for Radiation Therapy



Atrys market cap evolution (€M) **BME Growth**



Share turnover (€M)



Since its IPO in June 2016 in BME growth, the ATRYS share has experienced a 601% revaluation versus a 9.1% revaluation of the IBEX-35 for the same period.


The IRR for ATRYS shareholder, from June 2016 to March 2021, was 50.37%.

Estimated market cap. after ASPY takeover bid: €600 M.

¹ Market cap at April 21, 2021

² 1S 2021 share turnover at April 21, 2021

ATRYs: Where we go – 2021/2022 strategic goals



- Expand the company's footprint in Europe through acquisitions.
- Accelerate diagnostic automation by incorporating AI tools in order to reduce costs and improve diagnostic quality.
- Enhance our data management through Smart/Big Data.
- Introduce new services in Europe (tele-consultation, chronics monitoring).
- Listing the Group in the Spanish main equity market (“*Mercado Continuo*”): improvement in liquidity, entry of international investment funds and exchange-traded fund (ETFs).
- Balance sheet structure and hidden assets optimization.
- Continue to create value for shareholders through organic growth, implementation of synergies and inorganic growth.



ANALYSIS OF 2020 RESULTS

2020 Main Figures

2020 Aggregated proforma:

Turnover

€45.1 M

-12% YoY
-4% YoY at constant
forex rate

Adj. EBITDA

€13.0 M

+28% YoY
28.8% / Turnover

Net Financial Debt

€42.4 M

+100% YoY
€32.6 M excluding Convertible
Bonds

Equity

€75.3 M

+89% YoY

FP/DFN

1.78x

2.31x excluding
Convertible Bonds

**Adj. EBITDA
per share**

€0.38

+34% YoY

NFD/Adj. EBITDA

3.3x

2.5x excluding
Convertible Bond
debt from NFD

**Operating
Cash Flow**

€8.0 M

+70,2% YoY

Aggregated Proforma = Includes full year impact of 2020 acquisitions (ITMS, Axismed and ICM)

Adjusted EBITDA = Does not include one-off expenses.

2020 – 2021 Guidance (Aggregated Proforma¹ figures)

For 2021, Atrys expects a +74% increase in the Group's Adjusted EBITDA per share on a proforma basis.

	2020 Guidance		2020 Reported		2021 Guidance
Turnover:	€45-47 M	✓	€45.1 M	⇒	€175.0 M
Adjusted EBITDA:	€13.0 M	✓	€13.0 M	⇒	€41.0 M
No of fully diluted shares:			34.6 M	⇒	61.8 M
Adj. EBITDA per share:			0.38 €	⇒	0.66 €

2021 Guidance based on constant exchange rate for the Chilean and Colombian peso as of end-Dec 2020 and full year financial impact of Lenitudes, ROAG and ASPY acquisitions.

¹ Aggregated Proforma = Includes full year impact of 2020 acquisitions (ITMS, Axismed and ICM) and 2021 acquisitions (Lenitudes, ROAG and ASPY)

Adjusted EBITDA = Does not include one-off expenses.

Income Statement 2020

(000) EUR	IFRS			Aggregated Proforma IFRS		
	31 Dec. 2019	31 Dec. 2020	Var. (%) 2019/20	31 Dec. 2019	31 Dec. 2020	Var. (%) 2019/20
Turnover	14.837	31.396	112%	51.207	45.133	-12%
Gross Margin	10.376	21.839	110%	29.834	30.503	2%
% gross margin on turnover	69,9%	69,6%	-1%	58,3%	67,6%	16%
EBITDA	3.121	5.932	90%	8.153	7.922	-3%
Non recurrent expenses	1.478	3.755	154%	1.991	5.071	155%
Adjusted EBITDA	4.598	9.687	111%	10.143	12.993	28%
% adjusted EBITDA on turnover	31,0%	30,9%	0%	19,8%	28,8%	45%
EBIT	1.215	1.919	58%	4.551	3.149	-31%
Adjusted EBIT	2.692	5.673	111%	6.542	8.220	26%
Net Profit	(105)	(2.015)	1823%	407	(2.532)	-722%
Adjusted Net Profit	1.373	1.740	27%	2.398	2.539	6%

¹ Information under IFRS only includes financials accrued from the effective incorporation of the acquired companies to Atrys Group.

² Aggregated Proforma = Includes full year impact of 2020 acquisitions (ITMS, Axismed and ICM) and full year impact of 2019 acquisitions (Real Life Data, Teleradiología de Combia, IMOR). It also includes full year impact of the financial expenses of the debt raised to carry out these acquisitions. Corporate Income tax has been recalculated accordingly.

Adjusted EBITDA and Adjusted Net Profit = Does not include one-off expenses.

- **Turnover:** Increased by 112% YoY reaching €31.4M at end-2020. On a proforma basis and at constant perimeter¹ turnover declined 12% YoY (-5% at constant exchange rates).

By regions, on a proforma basis, turnover in Spain increased 19% YoY while LatAm turnover decreased 33% YoY (-16% at constant exchange rates). The asymmetric behavior is due to:


- The hard-lockdown due to COVID-19 at the beginning of 2020 was shorter in Spain than in Chile and Colombia.
 - In LatAm, main activity is focused on Online Diagnostic, directly and significantly impacted by the closure of hospital activity during hard lockdowns periods.
 - Laboratory activity in Spain was successfully redirected to perform COVID-19 test during 2020, partially offsetting the impact of the pandemic in other areas.
- **Gross Margin:** On a proforma basis and at constant perimeter, it increased to 67.6% (from 58.3% in 2019) due to a lower weight in the Group's activity of the Online Diagnosis area, the most impacted by the COVID19 hard lockdowns.
 - **Adjusted EBITDA²:** improved 28% YoY reaching €13.0M, on a proforma basis and at constant perimeter, despite the 12% decrease in turnover. One-off expenses amounted €5.1M.
 - **Net Profit:** of -€2.0M, on a proforma basis and at constant perimeter, negatively impacted by one-off expenses of €5.1M (mainly related to M&A activity, capital increases and bond issuances). Adjusted Net Profit (excl. one-offs) reached €2.5M in 2020.

¹ Aggregated Proforma at constant perimeter= Includes full year impact of 2020 acquisitions (ITMS, Axismed and ICM) in 2019 and 2020 and full year impact of 2019 acquisitions (Real Life Data, Teleradiología de Colombia, IMOR) in 2019.


² Adjusted EBITDA = Does not include one-off expenses.

Aggregated Proforma¹ turnover evolution

Proforma turnover breakdown:
(€M)



Quartely proforma turnover evolution :
(€M)



Main variations during 2020 are due to (i) Latam Forex impact (-7%) and (ii) COVID19 impact in Latam DxO activities (-15%) due to long hard lockdown periods, partially offset by (iii) the positive evolution in Spain (+19%) due to COVID19 tests and (iv) Smart Data and Radiotherapy businesses performance.



During the Q4, Atrys returned to grow (+6% organically), after several quarters affected by the COVID19 situation.

- Hard lockdown in Spain from March to June.
- Hard lockdown in Chile and Colombia from March to September.
- Forex emerging markets devaluation from February to September.

¹ Aggregated Proforma = Includes full year impact of 2020 acquisitions (ITMS, Axismed and ICM) and full year impact of 2019 acquisitions (Real Life Data, Teleradiología de Combia, IMOR).

Turnover geographic distribution

The expected acquisitions in 1S21 are going to rebalance the Group's country risk exposure, switching from 44.2% of its turnover arising from emerging markets in 2020, to barely 15.7% in 2021.




¹ 2020 Aggregated Proforma = Includes full year impact of 2020 acquisitions (ITMS, Axismed and ICM).

² 2021 estimated Aggregated Proforma = Includes full year impact of 2021 acquisitions (Lenitudes, ROAG and ASPY).

Aggregated Proforma² adjusted EBITDA evolution

Adjusted EBITDA reconciliation: (€M)



One-off 2020 expenses detail: (€M)

One-off expenses 2020	Spain	Latam	Total
1) Personnel executed restructuring	0.3	1.6	1.9
2) M&A one-off related expenses	2.1	-	2.1
3) One-off expenses pre-acquisitions ³	-	1.1	1.1
Total one-off expenses 2020	2.5	2.7	5.1


¹ EBITDA from acquired companies not consolidated in the consolidated statutory accounts 2020.

² Aggregated Proforma = Includes full year impact of 2020 acquisitions (ITMS, Axismed and ICM).

³ One-off expenses accrued in the acquired companies in 2020 prior their acquisition and therefore only included in the proforma information.


Aggregated Proforma¹ operative cash flow² conversion

2019 Proforma operative cash flow:
(€M)



2019 RONA⁴: **19%**

2020 Proforma operative cash flow:
(€M)



2020 RONA⁴: **24%**

¹ Aggregated Proforma = Includes full year impact of 2020 acquisitions (ITMS, Axismed and ICM) and full year impact of 2019 acquisitions (Real Life Data, Teleradiología de Combia, IMOR).

² Operative cash flow: Adjusted EBITDA – Maintenance capex.

³ It does not include non-recurring investment in the IOA.

⁴ RONA = EBITDA / (Total non current assets – Goodwill not associated to cash – Deferred tax assets + Net Working Capital).

Equity Increase: €35M – July 2020.

Equity increase for institutional investors covered with a book demand of €110M.

2020 MARF Bond Programme: €50M – July 2020 / March 2021.

New MARF Bond Programme for a maximum of €50M due in 2025 (bullet scheme) fully disbursed (€30M in July and €20M in March 2021 via TAP).

€15M of the proceeds were used to amortize the 2019 MARF Bond Programme due in 2024.


Convertible Bond Debt: €10M – October 2020.

Convertible Bond subordinated to MARF Bond Programme, due in 2026 with an interest rate of 3.0% + 2.7% PIK.

Improved Group's and Debt ratings.

In 2020, Axesor upgraded ATRYS credit rating to BB- (from B) and Bonds issued under the 2020 Atrys Bond Programme in MARF to BB (from BB-).


2020 Consolidated Debt position: (€M)



2020 MARF Programme Debt covenants:

Ratios	2020		Limit
NFD / Adj.PF.EBITDA:	2.5x	✓	<4.0x
NFD ² / Adj.PF.EBITDA:	3.3x	✓	<4.0x
Net Equity / NFD:	1,8x	✓	>1,2x
Adj.PF.EBITDA/ Financial Exp:	6,2x	✓	>0,4x

Debt amortization calendar: (€M)




¹ Convertible Bond is subordinated by contract to the MARF Bond Programme. Strike conversion price at 6,0€ per Atrys share.

² Net financial Debt including Convertible Bond Debt.

³ Cash & Cash equivalents + undrawn balance of the credit facilities.

Note: the amortization of the Convertible Bond is contemplated in 2026. However, in 2022 the bondholders could execute the bond conversion at a strike conversion price of 6,0€ per Atrys share.



¹ EBITDA from acquired companies not consolidated in the consolidated statutory accounts 2020.

² Aggregated Proforma = Includes full year impact of 2020 acquisitions (ITMS, Axismed and ICM).

³ Adjusted EBITDA: One-off expenses accrued in the acquired companies in 2020 prior their acquisition and therefore only included in the proforma information.



Q&A



APPENDIX

Image ICM Genetyc Center in Lugo. Spain.

ATRY'S HEALTH S.A. Consolidated (000) EUR	Audited NIIF UE		
	Dec 31. 2019	Dec 31. 2020	Var. %
INCOME STATEMENT			
NET TURNOVER	14.837	31.396	112%
Purchases:	(4.461)	(9.558)	114%
GROSS MARGIN	10.376	21.839	110%
Other operating income:	24	599	2382%
Work carried out by the group for its assets:	1.822	2.412	32%
Allocations of grants:	298	311	4%
Employee expenses:	(5.219)	(11.033)	111%
Other operating expenses:	(4.167)	(8.359)	101%
Amortisation of fixed assets:	(1.906)	(3.825)	101%
Impairment and gains & losses fixed assets:	(0)	0	-100%
Other results:	(14)	(25)	75%
OPERATING PROFIT	1.214	1.919	58%
Financial income:	1	210	–
Financial expenses:	(1.113)	(2.494)	124%
Variation of fair value of financial instruments:	104	(32)	-130%
Exchange rate differences:	1	(911)	-65111%
FINANCIAL LOSS	(1.007)	(3.227)	221%
PRE TAX PROFIT/LOSS	207	(1.309)	-732%
Corporate income tax:	(311)	(707)	127%
PROFIT/LOSS	(104)	(2.015)	1829%

2020 Statutory Balance Sheet

ATRY'S HEALTH S.A. Consolidated (000) EUR	Audited NIIF UE		
	Dec 31. 2019	Dec 31. 2020	Var. %
ASSETS			
NON CURRENT ASSETS	70.017	138.512	98%
Intangible fixed assets:	55.002	121.533	121%
Property, plant and equipment:	5.738	9.843	72%
Investments in non consolidated companies:	22	31	40%
Non current financial assets:	3.619	1.300	-64%
Deferred tax assets:	5.635	5.805	3%
CURRENT ASSETS	18.026	37.264	107%
Inventories:	271	655	142%
Trade debtors and other accounts receivables:	8.289	17.036	106%
Current tax assets and public administrations:	682	1.607	135%
Current financial assets:	439	466	6%
Accrual accounts:	15	24	59%
Cash and cash equivalents:	8.329	17.476	110%
TOTAL ASSETS:	88.043	175.776	100%

ATRY'S HEALTH S.A. Consolidated (000) EUR	Audited NIIF UE		
	Dec 31. 2019	Dec 31. 2020	Var. %
EQUITY AND LIABILITIES			
EQUITY	39.954	75.328	89%
NON CURRENT LIABILITIES	38.270	79.038	107%
Long term provisions:	1.966	13.191	571%
Non Current financial debts:	5.411	10.077	86%
Other non current liabilities:	24.905	49.556	99%
Grants pending transfer to income:	5.829	5.714	-2%
Non current tax liabilities:	0	329	--
Deferred tax liabilities:	160	171	7%
CURRENTS LIABILITIES	9.819	21.410	118%
Short term provisions:	1.049	875	-17%
Current financial liabilities:	2.167	3.150	45%
Other current liabilities:	3.286	8.816	168%
Trade creditors and other accounts payables:	1.910	6.340	232%
Current tax liabilities:	1.056	1.696	61%
Grants pending transfer to income:	268	310	16%
Short term accrual accounts:	82	223	172%
TOTAL EQUITY AND LIABILITIES	88.043	175.776	100%

ATRY'S HEALTH S.A. Consolidado (000) EUR	Auditado NIIF UE		
	31 Dic. 2019	31 Dic. 2020	Var. %
ESTADO DE RESULTADOS			
CIFRA DE NEGOCIOS	14.837	31.396	112%
Aprovisionamientos:	(4.461)	(9.558)	114%
MARGEN BRUTO	10.376	21.839	110%
Otros ingresos de explotación:	24	599	2382%
Trabajos realizados por el grupo para su activo:	1.822	2.412	32%
Imputación subvenciones:	298	311	4%
Gastos de personal:	(5.219)	(11.033)	111%
Otros gastos de Explotación	(4.167)	(8.359)	101%
Amortizaciones del inmovilizado:	(1.906)	(3.825)	101%
Deterioro y resultados enajenación inmovilizado:	(0)	0	-100%
Otros resultados:	(14)	(25)	75%
RESULTADO DE EXPLOTACIÓN:	1.214	1.919	58%
Ingresos financieros:	1	210	--
Gastos financieros:	(1.113)	(2.494)	124%
Variación valor razonable instrumentos financieros:	104	(32)	-130%
Diferencias de cambio:	1	(911)	-65111%
RESULTADOS FINANCIEROS:	(1.007)	(3.227)	221%
RESULTADO ANTES DE IMPUESTOS	207	(1.309)	-732%
Impuesto sobre beneficios:	(311)	(707)	127%
RESULTADO DEL PERIODO:	(104)	(2.015)	1829%

2020 Balance consolidado contable

ATRY'S HEALTH S.A. Consolidado (000) EUR	Auditado NIIF UE		
	31 Dic. 2019	31 Dic. 2020	Var. %
ACTIVOS			
ACTIVOS NO CORRIENTES	70.017	138.512	98%
Inmovilizado intangible:	55.002	121.533	121%
Inmovilizado material:	5.738	9.843	72%
Inversiones en empresas del grupo no consolidadas:	22	31	40%
Non current financial assets:	3.619	1.300	-64%
Activos por impuestos diferidos:	5.635	5.805	3%
ACTIVOS NO CORRIENTES	18.026	37.264	107%
Existencias:	271	655	142%
Deudores comerciales y otras cuentas a cobrar:	8.289	17.036	106%
Activos por impuestos corrientes:	682	1.607	135%
Activos financieros corrientes:	439	466	6%
Periodificaciones:	15	24	59%
Efectivo y otros activos líquidos:	8.329	17.476	110%
TOTAL ACTIVO:	88.043	175.776	100%

ATRY'S HEALTH S.A. Consolidado (000) EUR	Auditado NIIF UE		
	31 Dic. 2019	31 Dic. 2020	Var. %
PATRIMONIO NETO Y PASIVO			
PATRIMONIO NETO	39.954	75.328	89%
PASIVO NO CORRIENTE	38.270	79.038	107%
Provisiones a largo plazo:	1.966	13.191	571%
Deudas financieras no corrientes:	5.411	10.077	86%
Otros pasivos no corrientes:	24.905	49.556	99%
subvenciones pendientes de traspasar a resultado:	5.829	5.714	-2%
Pasivos por impuestos no corrientes:	0	329	--
Pasivos por impuestos diferidos:	160	171	7%
PASIVO CORRIENTE	9.819	21.410	118%
Provisiones a corto plazo:	1.049	875	-17%
Deudas financieras corrientes:	2.167	3.150	45%
Otros pasivos corrientes:	3.286	8.816	168%
Acreedores comerciales y otras cuentas a pagar:	1.910	6.340	232%
Pasivos por impuestos corrientes:	1.056	1.696	61%
Subvenciones pendientes de traspasar a resultados:	268	310	16%
Periodificaciones a corto plazo:	82	223	172%
TOTAL PATRIMONIO NETO Y PASIVO:	88.043	175.776	100%

Terms and definitions

Gross Financial Debt (GFD):

Sum of all debts that generate a financial expense and which are pending payment as of December 31 of each year in the Consolidated Financial Statements prepared under IFRS except for (i) Debts without recourse to the holding company. (ii) Loans in shares granted by shareholders.

Net Financial Debt (NFD):

Gross Financial Debt as of December 21 of each year, less (i) cash, (ii) liquid financial assets and (iii) restricted cash set as guarantees linked to Public debt received to finance R&D projects.

EBITDA:

Earnings Before Interests, Taxes, Depreciations and Amortizations as per the Consolidated Annual Accounts under IFRS.

Adjusted EBITDA:

EBITDA of the year excluding one-off expenses (M&A expenses, financial expenses related to capital increases and bonds issuance to finance the M&A activity, stock options plan which do not imply a cash-out and cost synergies executed and verified by the Group's auditors.

Adjusted Aggregated Proforma EBITDA:

EBITDA of the year including the full year results of the companies acquired during the year, excluding one-off expenses (M&A expenses, financial expenses related to capital increases and bonds issuance to finance the M&A activity, stock options plan which do not imply a cash-out and cost synergies executed and verified by the Group's auditors.

2020 Aggregated Proforma:

Full year impact in the P&L Account of the acquisitions carried out during 2020: ITMS Group (07/2020); Axismed (08/2020) and ICM (10/2020).

2019 Aggregated Proforma:

Full year impact in the P&L Account of the acquisitions carried out during 2019: Real Life Data (06/19); Teleradiologia de Colombia (09/19) and IMOR (10/19).

2020 Aggregated Proforma EBITDA:

EBITDA of 2020 including the full year impact from the acquisitions carried out during 2020: ITMS Group (07/2020); Axismed (08/2020) and ICM (10/2020).

2019 Aggregated Proforma EBITDA:

EBITDA of 2019 including the full year impact from the acquisitions carried out during 2019: Real Life Data (06/19); Teleradiologia de Colombia (09/19) and IMOR (10/19).

Covenant:

Agreement between the Group and its lenders to keep certain limitations to the Group's indebtedness.

CAPEX:

Funds used by the Group to buy, improve, maintain or develop its tangible or intangible assets, such as buildings, machinery, technology or equipment.

R&D Capex:

Investment in assets related to the development of the Group's R&D activity.

Terms and definitions

COVID19:

The novel SARS-CoV-2 coronavirus is a new type of coronavirus that was first detected in December 2019 in Wuhan City, Hubei Province, China.

Group's Auditor:

It refers to BDO Auditores S.L.P.

Net assets / Shareholders equity:

As of 31th December of each year, it means the amount of the Caption Net Assets / Shareholders equity included in the Audited Consolidated Accounts. For the purposes of calculating the covenants, the Treasury Shares amount will be excluded from the Net Equity figure.

IOA:

Instituto de Oncología Avanzada

Thank you